Equities research analysts expect Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to post earnings of ($0.72) per share for the current quarter, Zacks reports. Five analysts have made estimates for Karyopharm Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.64) and the lowest estimate coming in at ($0.81). Karyopharm Therapeutics reported earnings of ($0.63) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 14.3%. The business is expected to announce its next earnings results on Tuesday, August 3rd.
According to Zacks, analysts expect that Karyopharm Therapeutics will report full-year earnings of ($2.67) per share for the current financial year, with EPS estimates ranging from ($2.86) to ($2.21). For the next financial year, analysts forecast that the firm will report earnings of ($1.58) per share, with EPS estimates ranging from ($2.22) to ($0.93). Zacks’ earnings per share calculations are an average based on a survey of analysts that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Sunday, May 2nd. The company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.06). The company had revenue of $23.26 million during the quarter, compared to the consensus estimate of $26.50 million. Karyopharm Therapeutics had a negative net margin of 177.34% and a negative return on equity of 357.73%.
Shares of NASDAQ KPTI traded down $0.22 during mid-day trading on Friday, hitting $9.14. The company had a trading volume of 9,411 shares, compared to its average volume of 1,093,861. The company has a 50-day moving average price of $9.78. The company has a debt-to-equity ratio of 2.33, a current ratio of 4.12 and a quick ratio of 4.07. Karyopharm Therapeutics has a one year low of $7.78 and a one year high of $19.40.
In other Karyopharm Therapeutics news, Director Garen G. Bohlin purchased 4,000 shares of the company’s stock in a transaction dated Thursday, May 6th. The stock was bought at an average cost of $7.82 per share, for a total transaction of $31,280.00. Following the completion of the transaction, the director now owns 4,000 shares in the company, valued at $31,280. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jatin Shah purchased 23,250 shares of the company’s stock in a transaction dated Friday, May 7th. The stock was acquired at an average price of $8.60 per share, with a total value of $199,950.00. The disclosure for this purchase can be found here. Company insiders own 10.24% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Penserra Capital Management LLC increased its stake in Karyopharm Therapeutics by 169.1% in the fourth quarter. Penserra Capital Management LLC now owns 1,690 shares of the company’s stock valued at $26,000 after acquiring an additional 1,062 shares during the last quarter. Rockefeller Capital Management L.P. increased its stake in Karyopharm Therapeutics by 54.5% in the first quarter. Rockefeller Capital Management L.P. now owns 3,400 shares of the company’s stock valued at $35,000 after acquiring an additional 1,200 shares during the last quarter. Captrust Financial Advisors increased its stake in Karyopharm Therapeutics by 600.0% in the fourth quarter. Captrust Financial Advisors now owns 3,500 shares of the company’s stock valued at $54,000 after acquiring an additional 3,000 shares during the last quarter. E Fund Management Co. Ltd. bought a new position in Karyopharm Therapeutics in the first quarter valued at approximately $118,000. Finally, Victory Capital Management Inc. bought a new position in Karyopharm Therapeutics in the first quarter valued at approximately $120,000. Institutional investors own 80.02% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company pioneering novel cancer therapies, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1.
Read More: What is an overbought condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.